Interestingly, in those studies that enrolled participants with both T2DM and HF, short-term treatment with different SGLT-2 inhibitors did not show an improvement of NT‐proBNP (12, 21, 22). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.